According to ADMA Biologics
's latest financial reports the company has A$0.14 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | A$75.37 M | -40.72% |
2022-12-31 | A$0.12 B | 80.42% |
2021-12-31 | A$70.46 M | -3.1% |
2020-12-31 | A$72.72 M | 90.33% |
2019-12-31 | A$38.2 M | 18.29% |
2018-12-31 | A$32.3 M | -41.5% |
2017-12-31 | A$55.21 M | 160.05% |
2016-12-31 | A$21.23 M | -7.98% |
2015-12-31 | A$23.07 M | -13.58% |
2014-12-31 | A$26.7 M | -18.11% |
2013-12-31 | A$32.6 M | 170.31% |
2012-12-31 | A$12.06 M | |
2011-06-30 | A$0 M | -44.24% |
2010-06-30 | A$0.01 M |